Published in Lancet on April 02, 2008
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet (2010) 2.72
The aging heart and post-infarction left ventricular remodeling. J Am Coll Cardiol (2011) 1.39
Hemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional procedures. J Neurointerv Surg (2012) 1.28
Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. Br J Clin Pharmacol (2011) 0.99
P2Y12 platelet inhibition in clinical practice. J Thromb Thrombolysis (2012) 0.97
Aspirin and clopidogrel resistance: methodological challenges and opportunities. Vasc Health Risk Manag (2010) 0.93
Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting. Vasc Health Risk Manag (2009) 0.90
Coronary artery revascularization in patients with diabetes mellitus. Circulation (2013) 0.89
Current concepts on antiplatelet therapy: focus on the novel thienopyridine and non-thienopyridine agents. Adv Hematol (2010) 0.89
Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options. Vasc Health Risk Manag (2012) 0.88
Our expanding view of platelet functions and its clinical implications. J Cardiovasc Transl Res (2010) 0.88
Immediate and Six-month Clinical Outcome of Percutaneous Coronary Intervention in a Tertiary Hospital in the Sultanate of Oman. Oman Med J (2008) 0.85
Implementing genotype-guided antithrombotic therapy. Future Cardiol (2010) 0.85
A pragmatic approach to sonothrombolysis in acute ischaemic stroke: the Norwegian randomised controlled sonothrombolysis in acute stroke study (NOR-SASS). BMC Neurol (2015) 0.81
Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Vasc Health Risk Manag (2009) 0.81
Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy. Cardiol Res Pract (2012) 0.81
Hotline update of clinical trials and registries presented at the ACC and SCAI-ACCi2 meeting 2008 in Chicago. Clin Res Cardiol (2008) 0.80
Genetic determinants of response to cardiovascular drugs. Curr Opin Cardiol (2012) 0.80
Acute promyelocytic leukemia as a cause of intracoronary drug-eluting-stent thrombosis. Tex Heart Inst J (2012) 0.80
P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use. Ther Adv Chronic Dis (2015) 0.80
Contemporary treatment of unstable angina and non-ST-segment-elevation myocardial infarction (part 2). Tex Heart Inst J (2010) 0.80
Impact of dual antiplatelet therapy with proton pump inhibitors on the outcome of patients with acute coronary syndrome undergoing drug-eluting stent implantation. ISRN Cardiol (2012) 0.79
Alternatives to clopidogrel for acute coronary syndromes: Prasugrel or ticagrelor? World J Cardiol (2010) 0.77
Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study. Eur J Clin Pharmacol (2014) 0.77
TRITON and beyond: new insights into the profile of prasugrel. Cardiovasc Ther (2011) 0.77
Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention. Ann Med (2011) 0.76
Case scenario: a patient on dual antiplatelet therapy with an intracranial hemorrhage after percutaneous coronary intervention. Anesthesiology (2014) 0.76
Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention. Pharm Pract (Granada) (2014) 0.76
A murine model of stent implantation in the carotid artery for the study of restenosis. J Vis Exp (2013) 0.76
Oral antiplatelet therapy for acute and chronic management of NSTE ACS: residual ischemic risk and opportunities for improvement. Cardiovasc Drugs Ther (2009) 0.75
Systematic review and meta-analysis of optimal P2Y12 blockade in dual antiplatelet therapy for patients with diabetes with acute coronary syndrome. Open Heart (2016) 0.75
Prasugrel versus clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. Curr Atheroscler Rep (2008) 0.75
New drugs approved in 2009. Proc (Bayl Univ Med Cent) (2010) 0.75
Stent thrombosis is a major concern in clinical practice: A single Saudi center experience. J Saudi Heart Assoc (2013) 0.75
Prolonged High-Dose Bivalirudin Infusion Reduces Major Bleeding Without Increasing Stent Thrombosis in Patients Undergoing Primary Percutaneous Coronary Intervention: Novel Insights From an Updated Meta-Analysis. J Am Heart Assoc (2016) 0.75
Intensive antiplatelet therapy for reduction of ischaemic events. Lancet (2008) 0.75
Prasugrel reduced ischemic outcomes more than did clopidogrel in patients receiving stents for ACS. ACP J Club (2008) 0.75
Intensive antiplatelet therapy for reduction of ischaemic events. Lancet (2008) 0.75
Intensity of antiplatelet therapy and percutaneous coronary intervention. F1000 Med Rep (2009) 0.75
Appropriate anti-thrombotic/anti-thrombin therapy for thrombotic lesions. Curr Cardiol Rev (2012) 0.75
Approaching an age of reason with antiplatelet therapy. Lancet (2008) 0.75
Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention. Vasc Health Risk Manag (2009) 0.75
Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel. Vasc Health Risk Manag (2009) 0.75
Safety and efficacy of antiplatelet response assay and drug adjustment in coil embolization: a propensity score analysis. Neuroradiology (2016) 0.75
Deterioration of renal function at stent implantation can predict long-term outcome after stent thrombosis. Wien Klin Wochenschr (2015) 0.75
Bariatric surgery: a systematic review and meta-analysis. JAMA (2004) 23.34
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med (2015) 13.90
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med (2011) 11.99
Universal definition of myocardial infarction. Circulation (2007) 11.69
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med (2013) 11.14
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
C-reactive protein levels and outcomes after statin therapy. N Engl J Med (2005) 9.47
Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med (2008) 9.25
Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med (2012) 8.28
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA (2011) 8.24
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med (2010) 7.39
Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet (2006) 7.33
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA (2004) 7.32
Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med (2005) 6.86
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81
Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation (2004) 6.34
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med (2013) 6.01
A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med (2009) 5.81
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med (2005) 5.28
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet (2002) 5.04
Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81
A tale of coronary artery disease and myocardial infarction. N Engl J Med (2012) 4.53
Full coverage for preventive medications after myocardial infarction. N Engl J Med (2011) 4.51
Myocardial infarction accelerates atherosclerosis. Nature (2012) 4.48
ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol (2002) 4.48
Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med (2015) 4.39
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet (2009) 4.31
Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol (2006) 4.16
Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med (2005) 4.13
Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med (2012) 4.10
Diabetes and mortality following acute coronary syndromes. JAMA (2007) 4.09